US FDA grants standard approval of Eisai/Biogen Alzheimer’s drug
By Deena Beasley and Julie Steenhuysen LOS ANGELES (Reuters) -Eisai and Biogen's…
N2:PHAR1
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
By Ludwig Burger FRANKFURT (Reuters) - Novartis breast cancer drug Kisqali cut the risk of…
J&J faces new trial over talc cancer claims, amid settlement push
By Brendan Pierson (Reuters) -Johnson & Johnson on Wednesday faced the first trial in…
Pfizer to raise $31 billion for Seagen takeover in largest debt…
(Reuters) -Pfizer Inc is planning to raise $31 billion through its largest debt offering…
Merck to build out immunology presence with $11 billion Prometheus…
By Michael Erman (Reuters) -Merck & Co said on Sunday it will buy Prometheus…
Analysis-Twitter’s advertising business seen facing slow…
By Sheila Dang (Reuters) - Twitter-owner Elon Musk has said advertisers are returning to…
J&J talc unit 2nd bankruptcy must be dismissed, cancer…
By Dietrich Knauth and Mike Spector (Reuters) -Johnson & Johnson’s second attempt to…
Exclusive-US to build $300 million database to fuel Alzheimer’s…
By Julie Steenhuysen CHICAGO (Reuters) - The U.S. National Institute on Aging (NIA) is…